Genzyme banks its future on cancer drugs
104872
When Genzyme Inc. breaks down its revenue this year, there's a big hole: treatment of cancer.
412704
NEW YORK (CBS.MW) -- The Food and Drug Administration has approved Genzyme Corp. and Bioenvision Inc.&#39;s treatment for the most common type of childhood leukemia, sending shares of both companies higher Wednesday.
185926
Genzyme Corp.  on Wednesday  reported second-quarter earnings that topped expectations on  higher sales of its drugs for rare and chronic diseases,  sending its shares up nearly 8 percent.
598449
NEW YORK  - An enzyme has been recently identified that is able to degrade gluten in a laboratory simulation of the gastrointestinal tract.
518363
The treatment that more cancer patients receive may one day depend on their genes
409761
Genzyme shows some sparkle at investors' conference.
702862
British scientists have discovered a new way to improve the effectiveness of drugs used to treat prostate cancer.
639985
As part of its push to become a bigger player in cancer drugs, Genzyme Corp. of Cambridge said yesterday it will buy out business partner Bioenvision Inc. of New York for $345 million , consolidating its ownership of a cancer treatment to which the two companies had been sharing rights.
12582
A vaccine to help patients fend of blood cancers could be a reality in the near future.
204544
Will Genzyme's Campath get approval?
560148
The Food and Drug Administration approved Clolar, Genzyme Corp.&#39;s new drug for patients under 21 with acute lymphocytic leukemia.
713941
GlaxoSmithKline Plc  has bought global rights to Danish biotech company Genmab's  most promising new drug, a treatment for leukemia, in a record deal worth up to $2.1 billion, the two firms said on Tuesday.
99180
THE REGION Cambridge biotech company Dyax Corp. has agreed to end its deal with Genzyme Corp. to codevelop a drug for the rare swelling disorder hereditary angioedema. The firms were jointly testing DX-88, a small protein considered Dyax's most important potential drug. Dyax said it will receive all the assets of the joint development deal and $17 million cash. Genzyme ...
171744
New drugs that are to be tested in connection with a phenomenon called RNA interference have excited scientists with their versatile and powerful ability to affect genes.
245176
Cancer was the biotech's biggest success story. Now to keep growing, it needs to branch out.
147168
The approval of a new drug is a long-term opportunity.
754072
Genzyme Corp.'s planned takeover of New York cancer drug maker Bioenvision Inc. has already hit a bump: A key Bioenvision shareholder is calling the deal a lowball offer and digging in against it.